Previous 10 | Next 10 |
2023-10-17 15:23:07 ET Summary Healthcare providers are undervalued by about 9% relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on iShares U.S. Healthcare Providers ETF, a healthcare providers fund. 10 stocks cheaper than the...
2023-10-09 13:48:03 ET Summary Innoviva, Inc. is a biopharma company focused on the development and commercialization of pharmaceutical products. However, the company's main asset is royalty revenues that come from products it receives from Glaxo Group Limited. There has been ...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference in New Yor...
XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems (CRAB). In the U.S., it is estimated there are more than 40,000 cases of Acinetoba...
2023-09-16 08:26:36 ET Summary The sector as a whole is overvalued by about 15% relative to 11-year averages. Healthcare providers and pharmaceuticals/biotechnology look fairly valued, whereas healthcare equipment is the less attractive subsector. IXJ: a global alternative to ...
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. ȁ...
2023-08-14 08:15:00 ET Summary This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is...
2023-08-02 17:26:02 ET Innoviva press release ( NASDAQ: INVA ): Q2 GAAP EPS of $0.02. Revenue of $80.99M (-25.2% Y/Y) beats by $13.07M . For further details see: Innoviva GAAP EPS of $0.02, revenue of $80.99M beats by $13.07M
Received GSK royalties of $65.7 million, net product revenues of $15.7 million and license revenue of $3.0 million in the second quarter of 2023 Received FDA approval for XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia cau...
2023-07-19 11:00:00 ET Summary Pharmaceuticals/biotechnology is the most attractive subsector regarding both value and quality scores. Healthcare equipment is the most overpriced healthcare industry. Fast facts on iShares U.S. Healthcare ETF. 10 healthcare stocks cheaper t...
News, Short Squeeze, Breakout and More Instantly...
2024-05-02 05:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Single-dose, oral zoliflodacin achieved 90.9% microbiological cure rate, demonstrating statistical non-inferiority compared to current global standard of care Pivotal Phase 3 data to be presented by the Global Antibiotic Research & Development Partnership (GARDP) in a Scientific S...
2024-04-12 13:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...